Melanie Majure, MD

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
Address550 16th Street, #001
San Francisco CA 94158
PronounsShe/Her/Hers
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Davidson College, Davidson, NCBS05/2000Neuroscience
    Stanford University School of Medicine, Stanford, CAMD06/2009
    Stanford University Hospital and Clinics, Stanford, CA10/2012Internal Medicine Residency
    UCSF, San Francisco, CA11/2015Hematology/Oncology Fellowship

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. 381P Treatment rechallenge after grade 1 trastuzumab-deruxtecan related interstitial lung disease: A real-world experience. Annals of Oncology. 2024 Sep 1; 35:s378. Natsuhara NK, Vella VM, Behr BS, Quintal QL, Chien CJ, Melisko MM, Majure MM, Buckle BG, Ko KA, Rugo RH. .
      View in: Publisher Site   Mentions:
    2. Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study. Breast Cancer Res Treat. 2024 Aug; 206(3):625-636. Huppert LA, Fisch S, Tsopurashvili E, Somepalle SS, Salans M, Vasudevan HN, Jo Chien A, Majure M, Rugo HS, Balassanian R, Boreta L, Melisko ME. PMID: 38888796; PMCID: PMC11208257.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. A single center retrospective cohort study of patients with metastatic breast cancer and leptomeningeal disease: Updated survival data and subgroup analyses by breast cancer subtype. Journal of Clinical Oncology. 2024 Jun 1; 42(16_suppl):1108-1108. Fisch FS, Tsopurashvili TE, Somepalle SS, Salans SM, Vasudevan VH, Chien CA, Majure MM, Rugo RH, Balassanian BR, Boreta BL, Melisko MM, Huppert HL. .
      View in: Publisher Site   Mentions:
    4. Abstract PS11-03: Comparison of next-generation sequencing (NGS) results from the cerebrospinal fluid, peripheral blood, and systemic metastatic tumor tissue of patients with metastatic breast cancer (MBC) and leptomeningeal disease (LMD). Cancer Research. 2024 May 2; 84(9_Supplement):ps11-03-ps11-03. Huppert HL, Her HL, Hodgdon HC, Brain BS, Simmons SC, Chien CJ, Majure MM, Rugo RH, Magbanua MM, Balassanian BR, Melisko MM. .
      View in: Publisher Site   Mentions:
    5. Abstract PS14-03: Delayed and post-treatment immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors. Cancer Research. 2024 May 2; 84(9_Supplement):ps14-03-ps14-03. Jacob JS, Fisch FS, Face FC, Huppert HL, Quandt QZ, Quintal QL, Melisko MM, Majure MM, Chien CJ, Blaes BA, Rugo RH. .
      View in: Publisher Site   Mentions:
    6. Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer. Breast Cancer Res Treat. 2024 Apr; 204(3):509-520. Umashankar S, Li M, Blevins K, Kim MO, Majure M, Park J, Huppert LA, Melisko M, Rugo HS, Esserman L, Chien AJ. PMID: 38194132; PMCID: PMC10959837.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer. Breast Cancer Res Treat. 2024 Jan; 203(2):197-204. Gumusay O, Huppert LA, Magbanua MJM, Wabl CA, Assefa M, Chien AJ, Melisko ME, Majure MC, Moasser M, Park J, Rugo HS. PMID: 37815684; PMCID: PMC10787873.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    8. Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors. Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):e24091-e24091. Jacob JS, Quandt QZ, Melisko MM, Majure MM, Chien CA, Blaes BA, Heditsian HD, Esserman EL, Rugo RH. .
      View in: Publisher Site   Mentions:
    9. Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: A single center retrospective cohort study. Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):1108-1108. Huppert HL, Tsopurashvili TE, Somepalle SS, Chien CA, Majure MM, Rugo RH, Balassanian BR, Melisko MM. .
      View in: Publisher Site   Mentions:
    10. Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC). Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):1091-1091. Huppert HL, Gliwa GA, Tait TM, Quintal QL, Starzinski SS, Cheung CA, Moasser MM, Majure MM, Melisko MM, Rugo RH, Munster MP, Campbell CM, Fong FL, Chien CA. .
      View in: Publisher Site   Mentions:
    11. Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study. Breast Cancer Res Treat. 2023 Jan; 197(1):137-148. Huppert LA, Walker Z, Li M, Kim MO, Callan J, Brandman D, Majure M, Melisko ME, Rugo HS, Behr S, Chien AJ. PMID: 36319907.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    12. Clinical and radiographic characteristics of patients with metastatic breast cancer and pseudocirrhosis: A single-center retrospective cohort study. Journal of Clinical Oncology. 2022 Jun 1; 40(16_suppl):1101-1101. Huppert HL, Walker WZ, Li LM, Kim KM, Callan CJ, Majure MM, Melisko MM, Rugo RH, Behr BS, Chien CA. .
      View in: Publisher Site   Mentions:
    13. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. NPJ Breast Cancer. 2021 Oct 05; 7(1):131. Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ. PMID: 34611148; PMCID: PMC8492731.
      View in: PubMed   Mentions: 11  
    14. Characterizing attitudes related to child-bearing in young women diagnosed with early breast cancer (EBC). Journal of Clinical Oncology. 2021 Oct 1; 39(28_suppl):165-165. Umashankar US, Li LM, Kim KM, Rugo RH, Melisko MM, Majure MM, Park PJ, Esserman EL, Chien CA. .
      View in: Publisher Site   Mentions:
    15. Abstract PS2-19: Circulating tumor cell (CTC) enumeration in a phase II trial of pazopanib in addition to endocrine therapy in patients with hormone resistant advanced breast cancer (ABC). Cancer Research. 2021 Feb 15; 81(4_Supplement):ps2-19-ps2-19. Gumusay GO, Magbanua MM, Majure MM, Deal DT, Renslo RJ, Wabl WC, Melisko MM, Chien CA, Goga GA, Moasser MM, Park PJ, Hwang HJ, Rugo RH. .
      View in: Publisher Site   Mentions:
    16. A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):1076-1076. Chien CA, Gliwa GA, Rahmaputri RS, Dittrich DH, Majure MM, Rugo RH, Melisko MM, Munster MP, Park PJ, Moasser MM, Matloubian MM, Lea LT, Rohrberg RJ, Krings KG, Goga GA. .
      View in: Publisher Site   Mentions:
    17. A phase Ib/II study of eribulin with cyclophosphamide (EC) in patients (pts) with advanced breast cancer (ABC). Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):e13079-e13079. Gumusay GO, Renslo RJ, Wabl WC, Chien CA, Melisko MM, Majure MM, Rahmaputri RS, Moasser MM, Park PJ, Rugo RH. .
      View in: Publisher Site   Mentions:
    18. Pazopanib (PZ) plus endocrine therapy as treatment for hormone resistant advanced breast cancer (ABC). Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):1068-1068. Gumusay GO, Majure MM, Deal DT, Renslo RJ, Wabl WC, Melisko MM, Chien CA, Goga GA, Moasser MM, Park PJ, Hwang HJ, Rugo RH. .
      View in: Publisher Site   Mentions:
    19. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020 05 01; 6(5):676-684. Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. PMID: 32053137; PMCID: PMC7058271.
      View in: PubMed   Mentions: 259     Fields:    Translation:HumansCTClinical Trials
    20. Fitbit Usage in Patients With Breast Cancer Undergoing Chemotherapy. Clin Breast Cancer. 2019 12; 19(6):443-449.e1. Dreher N, Hadeler EK, Hartman SJ, Wong EC, Acerbi I, Rugo HS, Majure MC, Chien AJ, Esserman LJ, Melisko ME. PMID: 31285177.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    21. A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 2019 May 20; 37(15_suppl):1072-1072. Chien CA, Rahmaputri RS, Dittrich DH, Majure MM, Rugo RH, Melisko MM, Goga GA. .
      View in: Publisher Site   Mentions:
    22. The value of embedding: integrated palliative care for patients with metastatic breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):703-708. Rabow M, Small R, Jow A, Majure M, Chien A, Melisko M, Belkora J, Esserman LJ, Rugo H. PMID: 29086230.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    23. Objective assessment of physical activity during chemotherapy for breast cancer. Journal of Clinical Oncology. 2017 May 20; 35(15_suppl):tps6626-tps6626. Melisko MM, Hadeler HE, Nelson NS, Lunde LA, Acerbi AI, Rugo RH, Majure MM, Chien CA, Esserman EL, Hartman HS. .
      View in: Publisher Site   Mentions:
    24. What the blood knows: interrogating circulating tumor DNA to predict progression of minimal residual disease in early breast cancer. Ann Transl Med. 2016 Dec; 4(24):543. Majure M, Logan AC. PMID: 28149904; PMCID: PMC5233500.
      View in: PubMed   Mentions: 2  
    25. Referral patterns among patients with metastatic breast cancer in an integrated palliative care program. Journal of Clinical Oncology. 2016 Oct 9; 34(26_suppl):163-163. Small SR, Belkora BJ, Majure MM, Chien CA, Melisko MM, Rugo RH, Rabow RM. .
      View in: Publisher Site   Mentions:
    26. Addition of pazopanib (PZ) to endocrine therapy in hormone resistant advanced breast cancer (ABC). Journal of Clinical Oncology. 2016 May 20; 34(15_suppl):560-560. Majure MM, Gasol Cudós GA, Angelidakis AA, Melisko MM, Karwat KA, Chien CA, Goga GA, Moasser MM, Park PJ, DeLuca DA, Rugo RH. .
      View in: Publisher Site   Mentions:
    27. Abstract P5-08-06: Comparison of risk prediction with the 21-gene recurrence score (oncotype DX) and the 70-gene signature (MammaPrint) in patients with estrogen receptor-positive early stage breast cancer. Poster Session Abstracts. 2016 Feb 15; p5-08-06-p5-08-06. Jiang JH, Denduluri DN, Majure MM, Favret FA, Rugo RH. .
      View in: Publisher Site   Mentions:
    28. Integrating outpatient palliative care into a metastatic breast oncology clinic. Journal of Clinical Oncology. 2015 Oct 10; 33(29_suppl):154-154. Small SR, Belkora BJ, Jow JA, Rabow RM, Majure MM, Melisko MM, Chien CA, Rugo RH. .
      View in: Publisher Site   Mentions:
    29. Role of pazopanib (PZ) in modulating hormone resistance in advanced breast cancer (ABC). Journal of Clinical Oncology. 2015 May 20; 33(15_suppl):529-529. Majure MM, Melisko MM, Karwat KA, Chien CA, Goga GA, Moasser MM, Park PJ, DeLuca DA, Rugo RH. .
      View in: Publisher Site   Mentions:
    30. Management of Metastatic Breast Cancer. Breast Disease. 2015 Jan 1; 473-497. Keck KS, Majure MM, Rugo RH. .
      View in: Publisher Site   Mentions:
    31. Maintenance of tolerance by regulation of anti-myeloperoxidase B cells. J Am Soc Nephrol. 2008 Sep; 19(9):1763-73. Bunch DO, Silver JS, Majure MC, Sullivan P, Alcorta DA, Chin H, Hogan SL, Lindstrom YI, Clarke SH, Falk RJ, Nachman PH. PMID: 18650487; PMCID: PMC2518447.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    32. Inhalation of Francisella novicida Delta mglA causes replicative infection that elicits innate and adaptive responses but is not protective against invasive pneumonic tularemia. Microbes Infect. 2008 Jun; 10(7):773-80. West TE, Pelletier MR, Majure MC, Lembo A, Hajjar AM, Skerrett SJ. PMID: 18539500; PMCID: PMC2657097.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    33. Adeno-associated virus vector expressing nerve growth factor enhances cholinergic axonal sprouting after cortical injury in rats. J Neurosci. 2003 Apr 01; 23(7):2797-803. Ramirez JJ, Caldwell JL, Majure M, Wessner DR, Klein RL, Meyer EM, King MA. PMID: 12684466; PMCID: PMC6742064.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    34. Severe laryngomalacia and bronchomalacia in DiGeorge syndrome and CHARGE association. Pediatr Pulmonol. 1997 Nov; 24(5):364-9. Markert ML, Majure M, Harville TO, Hulka G, Oldham K. PMID: 9407570.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    35. A common presentation of an uncommon cause of neonatal respiratory distress: pneumonia alba. Pediatr Pulmonol. 1993 Jun; 15(6):376-9. Edell DS, Davidson JJ, Mulvihill DM, Majure M. PMID: 8337016.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    36. Unusual manifestation of Stevens-Johnson syndrome involving the respiratory and gastrointestinal tract. Pediatrics. 1992 Mar; 89(3):429-32. Edell DS, Davidson JJ, Muelenaer AA, Majure M. PMID: 1741216.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    37. Risk factors for the development of posterior subcapsular cataracts in patients with cystic fibrosis and allergic bronchopulmonary aspergillosis treated with corticosteroids. Pediatr Pulmonol. 1989; 6(4):260-2. Majure M, Mroueh S, Spock A. PMID: 2748222.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    Melanie's Networks
    Concepts (127)
    Derived automatically from this person's publications.
    _
    Co-Authors (25)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _